HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
Through this collaboration, samples collected by OmiCure will be sent to HTG’s VERI/O® laboratory in
HTP utilizes the proprietary HTG EdgeSeq® system, requiring only a fraction of the tissue biopsy material used by other systems to analyze nearly 20,000 genes. HTG EdgeSeq’s comprehensive gene expression data can be available in as few as three days, far faster than more conventional methods like RNA-Seq, and is less dependent on sample quality.
OmiCure leverages Onco KEM, an AI-transcriptional-based therapeutic recommendation-tool, which has been tested in an international multi-center clinical trial. This technology matches patients’ tumor RNA profiles with comprehensive databases of existing therapies and scores them according to their potential actions.
“We are thrilled that OmiCure has chosen to leverage HTG’s innovative technology to advance precision medicine for diverse types of cancers,” said
“Providing fast and accurate information is of the utmost importance to us so that healthcare providers can leverage precision medicine and give patients the best chance at an optimal outcome,” said
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
OmiCure is a leading European digital health company, that develops and markets explainable AI-based therapeutic decision support software. OmiCure’s range of products provide physicians with the support they need when making complex cancer treatment decisions. OmiCure’s technology combines a proprietary advanced analytical explainable AI platform, with a comprehensive knowledgebase of scientific and medical advances. It has the power to analyze clinically relevant cancer biomarkers from DNA, RNA and protein profiles, from both solid and liquid biopsies. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile.
OmiCure provides worldwide access to state-of-the-art analyses to cancer centers, oncologists, and physicians, who aim to improve their therapeutic decision making in oncology. The AI platform processes molecular biology data, including sequencing data from NGS platforms, and turns them into clinical insights.
For more information, visit: www.omicure.com.
HTG Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding activities to be performed under the collaboration with OmiCure, the turnaround time for HTG EdgeSeq’s comprehensive gene expression data, expectations and beliefs regarding the combination of HTP data with OmiCure’s AI technology, Onco KEM, and its potential to inform critical decisions, and the capabilities, applications and design benefits of HTP and HTG’s proprietary RNA platform technologies. Words such as “can be,” “designed to,” “believes,” “expects,” “potential,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the HTP or our RNA platform technology may not perform as expected or provide the benefits that we expect; uncertainties regarding the effectiveness of using HTG’s and OmiCure’s respective technologies in combination; risks related to reliance on third parties to perform under collaborations or other contractual arrangements; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 12, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
HTG Investor Contact:
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.